Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Early Phase 1

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05986851Phase 2Active Not Recruiting

Azeliragon in MGMT Unmethylated Glioblastoma

Role: lead

NCT05635734Phase 1Active Not Recruiting

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Role: lead

NCT06831526Early Phase 1Recruiting

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Role: collaborator

NCT05766748Phase 1Recruiting

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Role: lead

NCT03714555Phase 2Terminated

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Role: collaborator

NCT04521335Phase 1Terminated

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Role: collaborator

NCT02963051Phase 1Terminated

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Role: collaborator

NCT03034135Phase 2Completed

Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Role: lead

NCT02995655Phase 1Completed

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Role: collaborator

All 9 trials loaded